Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium.
Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Department of Pharmacy, University of Liege (ULiege), Avenue Hippocrate 15, 4000 Liege, Belgium.
Int J Pharm. 2023 Jul 25;642:123131. doi: 10.1016/j.ijpharm.2023.123131. Epub 2023 Jun 13.
Hydrocortisone is mainly used in the substitution treatment of adrenal insufficiency which results in a dysregulation of cortisol. Compounding of hydrocortisone capsules remains the only low-dose oral treatment suitable for the pediatric population. However, capsules often show non-compliance in mass and content uniformity. Three-dimensional printing offers the prospect of practising personalized medicine for vulnerable patients like children. The goal of this work is to develop low-dose solid oral forms containing hydrocortisone by hot-melt extrusion coupled with fused deposition modeling for the pediatric population. Formulation, design and processes temperatures were optimized to produce printed forms with the desired characteristics. Red mini-waffle shapes containing drug loads of 2, 5 and 8 mg were successfully printed. This new 3D design allow to release more than 80 % of the drug in 45 min indicating a conventional release like the one obtained with capsules. Mass and content uniformity, hardness and friability tests complied with European Pharmacopeia specifications, despite the considerable challenge of the small dimensions of the forms. This study demonstrates that FDM can be used to produce innovative pediatric-friendly printed shapes of an advanced pharmaceutical quality to practice personalize medicine.
氢化可的松主要用于治疗因皮质醇失调而导致的肾上腺功能不全的替代治疗。配制氢化可的松胶囊仍然是唯一适合儿科人群的低剂量口服治疗方法。然而,胶囊在质量和含量均匀性方面常常表现出不达标。三维打印为儿童等脆弱患者提供了实施个体化医疗的前景。这项工作的目的是通过热熔挤出与熔融沉积建模相结合,为儿科人群开发含有氢化可的松的低剂量固体口服制剂。优化了配方、设计和工艺温度,以生产具有所需特性的打印制剂。成功打印了含有 2、5 和 8mg 药物的红色迷你华夫形状。这种新的 3D 设计可以在 45 分钟内释放超过 80%的药物,表明其释放方式与胶囊一样具有常规释放特性。尽管面临着制剂尺寸较小的巨大挑战,但质量和含量均匀性、硬度和脆碎度测试均符合欧洲药典的规定。本研究表明,FDM 可用于生产具有创新性的、适合儿科使用的、具有先进药物质量的打印制剂,以实施个体化医疗。